Prestigious journal prints results from Cuba’s Soberana Plus vaccine

Havana, Jun 10 (Prensa Latina) The Lancet Respiratory Medicine published the results from Phases 2a and 2b of clinical trials on Cuba's Covid-19 Soberana Plus vaccine, the Finlay Vaccine Institute (IFV), its developer, noted on Friday.

The vaccine, the source pointed out, demonstrated effectiveness in reinforcing immunity against different variants of the SARS-CoV-2 coronavirus,

The Lancet Respiratory Medicine, an authorized forum for key opinion leaders in medicine, has an impact factor of 30.7 and is a leader in the field, the Institute also recalled.

Since last year, Cuba has applied the heterologous scheme of two doses of Soberana 02 (also from the IFV) and a booster dose of Soberana Plus to part of its adult population, as well as to most of its pediatric population.

The latter also became the only preparation of its kind in the world authorized for children over two years old who are convalescing from Covid-19, the Cuban scientific institution informed.

In the results from the trials with children who suffered from the disease, safety was proven after the administration of one dose and the benefits against the potential risk of reinfection, it added.

Likewise, the Soberana Plus Turin clinical trial was carried out with this immunizer, designed to evaluate its efficacy in Covid-19 convalescents and subjects with no history of the disease, but previously immunized with other products.

The research, carried out on people between 19 and 59 years old living in Italy who received an inoculation of the vaccine, showed that it can be used as a booster dose for any other vaccine platform, since in all cases a reinforcement of immunity was observed, IFV Research Director Dagmar Garcia said recently.

In addition to Soberana 02 and Soberana Plus, the IFV is working on the Soberana 01.